ADA production was shown to be independent of tumor type, line of therapy, treatment dose, or administration as monotherapy or in combination with other drugs, while a male sex, Caucasian ethnicity, extended tumor burden, impaired liver function, a high level of serum C-reactive protein, NLR, and lactate dehydrogenase demonstrated a strong correlation with the development of ADA following ICIs therapy [163]. This evidence concerns the gene ADA and neoplasm.